4D Molecular Therapeutics (NASDAQ:FDMT) Receives “Sell (E+)” Rating from Weiss Ratings
Weiss Ratings reaffirmed their sell (e+) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a report published on Saturday morning,Weiss Ratings reports. A number of other equities analysts have also recently weighed in on FDMT. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of 4D […]
Weiss Ratings reaffirmed their sell (e+) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a report published on Saturday morning,Weiss Ratings reports. A number of other equities analysts have also recently weighed in on FDMT. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of 4D […]
